ERBB2 and neoplasm: Investigations of biomarkers, particularly microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation levels, and Epstein–Barr virus, have enabled the identification of populations most likely to benefit from immunotherapy and targeted therapies.